PTC Therapeutics' (PTCT) CEO Stuart Peltz on Q1 2017 Results - Earnings Call Transcript

May 08, 2017 11:36 AM ETPTC Therapeutics, Inc. (PTCT)
SA Transcripts profile picture
SA Transcripts
133.62K Followers

PTC Therapeutics (NASDAQ:PTCT) Q1 2017 Earnings Conference Call May 8, 2017 8:30 AM ET

Executives

Jane Baj - Investor Relations

Stuart Peltz - Chief Executive Officer

Mark Rothera - Chief Commercial Officer

Shane Kovacs - Executive Vice President, Chief Financial Officer and Head-Corporate Development

Analysts

Peter Stapor - Bank of America

Alethia Young - Credit Suisse

Ritu Baral - Cowen

Evan Seigerman - Barclays

Joel Beatty - Citi

Matthew Eckler - RBC Capital Markets

Operator

Good day, ladies and gentlemen, and welcome to the PTC Therapeutics First Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, there will be a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference call is being recorded.

I would now like to turn the conference over to Jane Baj. Ma'am you may begin.

Jane Baj

Thank you. Welcome to PTC’s call to discuss first quarter financial results, our plans for the Emflaza launch and other business updates.

Before we start, let me remind you that today’s call will include forward-looking statements based on current expectations. Forward-looking statements include all statements, other than those of historical facts including statements concerning financial guidance, our expectations with respect to the future commercial availability of and access to Emflaza including timing of the commercial launch, annual pricings and patient insurance mix, the anticipated benefits of the Emflaza acquisition, our future expectations regarding other clinical, regulatory and commercialization matters including with respect to potential outcome and anticipated timelines, addressable patient populations for Translarna and Emflaza and the potential success of Translarna for the treatment of nmDMD and Emflaza for the treatment of DMD.

Actual results may differ materially from expressed or implied by forward-looking statements as a result of a variety of risks and uncertainties

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.